Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Inflammation is likely a key contributor to the pathogenesis of Parkinson's disease (PD), a progressively debilitating neurodegenerative disease that is accompanied by a pathological accumulation of the α-synuclein protein in a staged manner through the brain. What leads to the accumulation of α-synuclein in PD and how this relates to inflammatory pathways, however, is not entirely clear. Toll-like receptor (TLR) signaling is a major pathway mediating inflammation and, in particular, TLR2 is increasingly being implicated in PD. We have, therefore, examined the expression of TLR2 in postmortem brain tissue from PD patients and matched controls. We confirm that TLR2 is increased in PD brain, and find that levels of TLR2 correlate with the accumulation of pathological α-synuclein. TLR2 was expressed on neurons as well as microglia; however, the neuronal rather than glial expression of TLR2 was significantly increased in PD brain in accordance with disease staging, and TLR2 was strongly localized to α-synuclein positive Lewy bodies. In cell culture, activation of neuronal TLR2 induced an inflammatory response, including the secretion of inflammatory cytokines and microglial-activating chemokines, as well as the production of reactive oxygen species. Moreover, activation of neuronal TLR2 increased levels of endogenous α-synuclein protein, which was in turn associated with increased levels of the autophagy/lysosomal pathway marker p62. Finally, promoting autophagy with rapamycin or pharmacological inhibition of the TLR2 signaling pathway prevented the TLR2-mediated increase in α-synuclein in neuronal cell cultures. These results implicate neuronal TLR2 expression in human PD pathogenesis. In particular, the increased expression of TLR2 on neurons may provide new insight into disease pathogenesis and/or options for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of neuronal TLR2 in the brains of patients with Parkinson's disease results in increased proinflammatory cytokine (TNF) levels and recruitment of microglia to amplify neuroinflammation as well as increased expression of asynuclein.158”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR2 also plays a role in neurons in response to α-synuclein in addition to microglia19,57,58.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.291,292”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [292]
The cited source says what the claim attributes to it.
In the citing paper
“TLR2 also plays a role in neurons in response to α-synuclein in addition to microglia19,57,58.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“Gene expression was quantified using the comparative Ct method [24] with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene.”
MethodStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Pathologically, PD is defined by the selective degeneration of dopamine-producing neurons in the substantia nigra pars compacta with concomitant accumulation of α-synuclein-rich proteinaceous neuronal inclusions, termed Lewy bodies, which propagate in a predicative or staged fashion through multiple brain regions [5,…”
BackgroundSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs mediate the recognition of exogenous conserved structures known as pathogen-associated molecular patterns (PAMPs) [18], and endogenous damage-associated molecular patterns (DAMPs) [33].”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“1 3 cytokines are increased in the brain, CSF and serum of PD patients [7, 17, 31] and activated microglia are prevalent in the most pathologically effected areas of the brains of patients with PD [26].”
Backgroundα-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins
Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R. L., & Akira, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.10 · Cited by 1,329 · cited 1×
“4b), which specifically activates TLR2/ TLR1 dimers [40].”
BackgroundZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 2×
“Recent reports have suggested that α-synuclein is a DAMP, capable of modulating inflammatory cytokine production in microglia [1, 3, 21, 39, 47].”
Background
Cited by
Items 101–200 of 280
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., Lopes, K. D. P., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00554-8 · Cited by 35
Sun, L., Jiang, W.-W., Wang, Y., Yuan, Y.-S., Rong, Z., Wu, J., Fan, Y., Lu, M., & Zhang, K.-Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00676-w · Cited by 31
“It is reported that TLR2 is increased in the brain of PD patients and correlates with pathological α-syn [32].”
Sian‐Hülsmann, J., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02723-5 · Cited by 32
Inflammation in Experimental Models of α‐Synucleinopathies
Harms, A. S., Kordower, J. H., Sette, A., Lindestam Arlehamn, C. S., Sulzer, D., & Mach, R. H. (2021) · Movement Disorders · doi:10.1002/mds.28264 · Cited by 29
“Binding of α-synuclein to TLR2 on microglia induces proinflammatory cytokine release,(57,58) and of note, TLR2 expression on neurons and ionized calcium binding adaptor molecule 1 (IBA1) + cells is increased in the PD brain relative to neurological controls.(55) Concurrently, it has been shown that α-synuclein interac…”
BackgroundChung, L. Y.-R., Lin, Y., Liu, C., Tai, Y., Lin, H., Lin, C., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845930 · Cited by 35
Jayakumar, T., Yang, C., Yen, T., Hsu, C.-Y., Sheu, J., Hsia, C., Manubolu, M., Huang, W.-C., Hsieh, C.-Y., & Hsieh, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115889 · Cited by 32
“This result indicates that Rut has the ability to inhibit both TLR2- and TLR4-receptors-mediated inflammatory markers.”
BackgroundInfluentialExpression and function of toll-like receptor 2 in vertebrate
Pergolizzi, S., Fumia, A., D’Angelo, R., Mangano, A., Lombardo, G. P., Giliberti, A., Messina, E., Alesci, A., & Lauriano, E. R. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152028 · Cited by 31
Genetic targeting of astrocytes to combat neurodegenerative disease
Kirschen, G., Kéry, R., & Chen, A. F. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.265541 · Cited by 30
“…receptor 2, a protein frequently over-expressed in post-mortem tissue taken from patients with PD and Lewy body dementia (Doorn et al., 2014; Dzamko et al., 2017), may mediate the transmission of α-synuclein between neurons and glia (Kim et al., 2018), and appears to trigger microglial…”
BackgroundWang, Y., Zhang, X., Chen, F., Chen, L., Wang, J., & Xie, J. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s301531 · Cited by 30
Mesecar, M. E., Duffy, M. F., Acri, D. J., Ding, J., Langston, R. G., Shah, S. I., Nalls, M. A., Reed, X., Scholz, S. W., Whitaker, D. T., et al. (2026) · npj Aging · doi:10.1038/s41514-026-00391-9 · Cited by 30
Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments
Chelpin, M. V. E., & Vorup‐Jensen, T. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12542 · Cited by 30
Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases
Narayanankutty, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666190222181506 · Cited by 29
Positron emission tomography tracers for synucleinopathies
Xiang, J., Zhang, Z., Wu, S., & Ye, K. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00787-9 · Cited by 29
Mixed pathology as a rule, not exception: Time to reconsider disease nosology
Chu, Y., Hirst, W. D., & Kordower, J. H. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00012-2 · Cited by 29
Weiss, F. C., Hughes, L. P., Fu, Y., Bardy, C., Halliday, G. M., & Dzamko, N. L. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00448-3 · Cited by 26
“TLR2 is increased on neurons in the PD brain and associated with increased levels of α-syn pathology [8].”
InfluentialSelf-citationIba, M., McDevitt, R. A., Kim, C., Roy, R., Sarantopoulou, D., Tommer, E., Siegars, B., Sallin, M. A., Kwon, S., Sen, J. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00564-6 · Cited by 26
“C For example, it has been shown that ɑ -syn can activate innate immune responses via Toll like receptors [26, 29–33].”
MethodRetractedHull, A. J., Atilano, M. L., Gergi, L., & Kinghorn, K. J. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0381 · Cited by 30
“Elevated levels of TLR2 and TLR4 expression are observed in brain regions pathologically affected by PD (i.e. SN pars compacta and putamen) and in myeloid cells of the post-mortem brains of PD patients [75,106].”
McCabe, K., Concannon, R. M., McKernan, D. P., & Dowd, E. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.07.007 · Cited by 27
“…is now growing evidence supporting the role of TLRs in the pathogenesis of several neurodegenerative diseases including Parkinson's disease with studies reporting upregulation of TLR2 and TLR4 in the human Parkinson's disease brain post mortem (DrouinOuellet et al., 2014; Dzamko et al., 2016).”
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
The role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 25
“In line with these results, blocking the interaction between TLR2 and MyD88 can reduce the activation of glial cells, decrease α-synuclein spreading, and protect dopaminergic neurons [211, 213, 214].”
ResultMichalska, P., Buendía, I., Duarte, P., Fernández‐Mendívil, C., Negredo, P., Cuadrado, A., López, M. G., & Leon, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104597 · Cited by 25
Drobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
Wang, J., Chen, Z., Walston, J. D., Gao, P., Gao, M., & Leng, S. X. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1567-5 · Cited by 25
“In memory impairment model in vivo, α-syn oligomers impair memory through TLR2-mediated glial cell activation [24], and in PD brain, TLR2 expression is significantly increased in neurons and shows a strong colocalization with α-syn in Lewy bodies [38].”
How Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis
Zhang, Z., Liu, Z., Lv, A., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154626 · Cited by 27
Li, H., Qian, J., Wang, Y., Wang, J., Mi, X., Qu, L., Song, N., & Xie, J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102288 · Cited by 23
Toll-like receptor 2 confers partial neuroprotection during prion disease
Carroll, J. A., Race, B., Williams, K., & Chesebro, B. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208559 · Cited by 22
Hurley, M. J., Menozzi, E., Koletsi, S., Bates, R., Gegg, M. E., Chau, K.-Y., Blottière, H. M., Macnaughtan, J., & Schapira, A. H. V. (2023) · Brain Communications · doi:10.1093/braincomms/fcad285 · Cited by 22
“48 Knocking out TLR2 in transgenic mice expressing human A53T α -synuclein reduced levels of α -synuclein.”
The Innate and Adaptive Immune Cells in Alzheimer’s and Parkinson’s Diseases
Huang, B., Zhenxin, Y., Chen, S., Tan, Z., Zong, Z., Zhang, H., & Xiong, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1315248 · Cited by 23
Prolonged STAT1 activation in neurons drives a pathological transcriptional response
Clark, D. N., O’Neil, S. M., Xu, L., Steppe, J. T., Savage, J. T., Raghunathan, K., & Filiano, A. J. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578168 · Cited by 22
Abdelaziz, A. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114692 · Cited by 20
A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology
Chedid, J., Labrador‐Garrido, A., Zhong, S., Gao, J., Zhao, Y., Perera, G., Kim, W. S., Halliday, G. M., & Dzamko, N. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102260 · Cited by 20
“Briefly, primary fibroblasts at passage four were reprogrammed to iPSCs using the EPi5 reprogramming kit (Life Technologies) as per the manufacturer instructions and as we have detailed before (7).”
BackgroundMethodSelf-citationSingh, G., & Khatri, D. K. (2024) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-024-00445-6 · Cited by 20
Deng, Y., Liu, K., Pan, Y., Ren, J., Shang, J., Chen, L., & Liu, H. (2020) · Sleep And Breathing · doi:10.1007/s11325-020-02030-3 · Cited by 20
“TLR2 is involved in the pathophysiology of a variety of neural morbidities, such as Parkinson’s disease [12], Alzheimer’s disease [13], and especially the cerebral hypoxia/ischemia (I/R) injury [14–18].”
BackgroundLRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation
Zhao, Y., Keshiya, S., Perera, G., Schramko, L., Halliday, G. M., & Dzamko, N. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105049 · Cited by 20
“The generation of the wild type cells has been described before [30], and data is provided again for convenience.”
BackgroundSelf-citationDelgado-Minjares, K. M., Martínez‐Fong, D., Martínez-Dávila, I. A., Bañuelos, C., Gutiérrez-Castillo, M. E., Blanco-Álvarez, V. M., Cárdenas‐Aguayo, M. D. C., Luna‐Muñoz, J., Pacheco‐Herrero, M., & Soto-Rojas, L. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111702 · Cited by 21
Tiwari, R. K., Moin, A., Rizvi, S. M. D., Shahid, S. M. A., & Bajpai, P. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00696-6 · Cited by 20
Dual Roles of Microglia in the Basal Ganglia in Parkinson’s Disease
Choudhury, M. E., Kigami, Y., & Tanaka, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083907 · Cited by 19
Jiang, W., Cheng, Y., Wang, Y., Wu, J., Rong, Z., Sun, L., Zhou, Y., & Zhang, K. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03345-4 · Cited by 18
“TLR2 is highly expressed in the influenced brain areas of PD and related to the level of aberrant α-syn [56].”
BackgroundHMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease
Tian, Y., Chen, R., & Su, Z. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01170-8 · Cited by 19
“Higher levels of HMGB1, TLR2, TLR4 and RAGE were detected in PD patients and animal models, indicating that HMGB1 and the signaling pathways downstream of these three receptors play roles in PD (Dzamko et al. 2017; Zhang et al. 2013).”
BackgroundBai, X., Luo, Y., Fan, W., Zhang, Y.-M., & Liao, X. (2022) · Plant Foods for Human Nutrition · doi:10.1007/s11130-022-01016-8 · Cited by 18
“It is characterized by motor symptoms including akinesia, muscle rigidity, tremor at rest, gait disorders, as well as non-motor symptoms including depression, sleep disturbance, and fatigue [2].”
BackgroundBrand-Rubalcava, P. A., Tejeda-Martínez, A. R., González‐Reynoso, O., Nápoles-Medina, A. Y., Chaparro-Huerta, V., & Flores-Soto, M. E. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105906 · Cited by 18
Greenland, J. C., Holbrook, J. A., Kahanawita, L., Camacho, M., Fryer, T. D., Hong, Y. T., & Williams‐Gray, C. H. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.028 · Cited by 18
“…in post mortem studies (Drouin-Ouellet et al., 2014), the expression of TLR2 correlates and localises with alpha-synuclein pathological burden (Dzamko et al., 2017) and the TLR2 pathway mediates the inflammatory response to oligomeric alpha-synuclein in vitro (Dzamko et al., 2017; Kim et al.,…”
AMPK signaling pathway as a potential therapeutic target for Parkinson's disease
Athari, S. Z., Farajdokht, F., Keyhanmanesh, ., & Mohaddes, G. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.013 · Cited by 22
Zhang, J., Tang, T. F., Zhang, R., Wen, L., Deng, X., Xu, X., Yang, W., Jin, F., Cao, Y., Lu, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108795 · Cited by 23
TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice
Kim, Y., Ryu, S.-H., Hyun, J., Cho, Y.-J., & Jung, Y. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.002 · Cited by 19
“Since TLR2 was reported to be expressed with low levels in neurons and high levels in microglia (Tang et al., 2007; Dzamko et al., 2017), we first examined whether TLR2 in neurons plays a role in tau uptake.”
BackgroundMercado, G., Käufer, C., Richter, F., & Peelaerts, W. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240195 · Cited by 20
“245 − 247 These observations have led to the hypothesis that astroglial TLR2 could play a dual role in synucleinopathies.”
BackgroundInfluentialKhan, A., Johnson, R., Wittmer, C., Maile, M., Tatsukawa, K. J., Wong, J. L., Gill, M. B., Stocking, E. M., Natala, S. R., Paulino, A., et al. (2021) · Brain · doi:10.1093/brain/awab214 · Cited by 17
Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Otero, M. D. C., Espinosa‐Oliva, A. M., Herrera, A. J., García-Domínguez, I., Arévalo, M. F., Martín‐Banderas, L., & de Pablos, R. M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180403113015 · Cited by 20
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?
Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 16
Upregulation of Neuroinflammation-Associated Genes in the Brain of SARS-CoV-2-Infected Mice
Oh, S. J., Kumari, P., Auroni, T. T., Stone, S., Pathak, H., Elsharkawy, A., Natekar, J. P., Shin, O. S., & Kumar, M. (2024) · Pathogens · doi:10.3390/pathogens13070528 · Cited by 18
“Relevant to this information, the blockage of TLR2–MyD88 interaction prevented neuroinflammation and attenuated AD’s pathology [23,24].”
BackgroundThe Immunopathogenesis of Neuroinvasive Lesions of SARS-CoV-2 Infection in COVID-19 Patients
Alipoor, S. D., Mortaz, E., Varahram, M., Garssen, J., & Adcock, I. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.697079 · Cited by 17
“TLRs detect pathogenor damage-associated molecular patterns (PAMPs and DAMPs) that accrue due to cell damage and can trigger a chronic inflammatory process (61, 62).”
BackgroundBearoff, F. M., Dhavale, D. D., Kotzbauer, P. T., & Kortagere, S. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.12.006 · Cited by 16
The Impact of microRNAs on Mitochondrial Function and Immunity: Relevance to Parkinson’s Disease
Guedes, B. F. S., Cardoso, S. M., & Esteves, A. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051349 · Cited by 17
Thomas, R., Connolly, K. J., Brekk, O. R., Hinrich, A. J., Hastings, M. L., Isacson, O., & Hallett, P. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-41240-z · Cited by 18
TLR4 and TLR2 activation is differentially associated with age during Parkinson’s disease
Sobrinho, H. M. D. R., da Silva, D. J., Gomides, L. F., Dorta, M. L., de Oliveira, M. A. P., & Ribeiro‐Dias, F. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1379024 · Cited by 17
“TLR2 is expressed in high levels in neurons and microglia associated with α-synuclein accumulation (Dzamko et al., 2017).”
BackgroundInfluentialMini-Review: Bioactivities of Bacterial Cell Envelopes in the Central Nervous System
MacCain, W. J., & TUOMANEN, E. I. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.588378 · Cited by 16
“Human neurons express TLR1, TLR2, TLR4, and CD14 for the recognition of LTA and the Lipid A portion of LPS (Acosta and Davies, 2008; Dzamko et al., 2017).”
BackgroundChen, S., Han, S., Hu, C.-F., Zhou, R., Gao, Y., Tu, D., Gao, H., Feng, J., Wang, Y., Lu, R., et al. (2022) · Antioxidants · doi:10.3390/antiox11061202 · Cited by 17
“Upregulation of TLRs expression was observed in a variety of chronic neurodegenerative diseases, such as Alzheimer’s disease (TLR2 and TLR4) [29,30], multiple sclerosis (TLR 1-8) [31], and Parkinson’s disease (TLR2 and TLR5) [13,32].”
BackgroundTLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson’ disease mice
He, Y., Zhao, J., Dong, H., Zhang, X., Duan, Y., Ma, Y., Yu, M., Fei, J., & Huang, F. P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122171 · Cited by 16
Aflouk, Y., Inoubli, O., Saoud, H., Zaâfrane, F., Gaha, L., & Jrad, B. B. H. (2021) · Immunologic Research · doi:10.1007/s12026-021-09238-9 · Cited by 15
Palmas, M. F., Etzi, M., Pisanu, A., Camoglio, C., Sagheddu, C., Santoni, M., Manchinu, M. F., Pala, M., Fusco, G., Simone, A. D., et al. (2022) · Cells · doi:10.3390/cells11172628 · Cited by 15
Prion-like propagation of α-synuclein in the gut-brain axis
Chen, Y., Shao, Q.-H., Yuan, Y., & Chen, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.002 · Cited by 16
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases
Choi, Y., & Chung, W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00870-9 · Cited by 16
“In the brains of DLB patients and αSyn transgenic mice, TLR2 expression is significantly elevated in both neurons [168] and microglia [167].”
Sánchez, K. E., & Maguire‐Zeiss, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.585544 · Cited by 16
“These findings are supported by other human studies and mouse models of PD, including A53T overexpressing mice, where TLR2 promotes neuroinflammation (Kim et al., 2015; Dzamko et al., 2017).”
ResultLee, E., Park, H., & Kim, S. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100089 · Cited by 13
“Illustrated images were generated using BioRender.com. signaling is associated with inflammation, while TLR2 levels have been found to be elevated in PD lesions, thereby facilitating neuroinflammation through microglial activation and cytokine release (Dzamko et al., 2017).”
The Intricate Interplay: Microbial Metabolites and the Gut‐Liver‐Brain Axis in Parkinson's Disease
Kishanchand, D. K., A., A. K. K., Chandrababu, K., Philips, C. A., Sivan, U., & Chakrapani, P. S. B. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70016 · Cited by 15
“Immunohistochemical studies confirm an association be-tween Toll-like receptor 2 (TLR2) and α-syn pathology in PD, as Lewy bodies positive to α-syn exhibit a marked TLR2 immunoreactivity (Dzamko et al. 2017).”
Arroyo, D. S., Gaviglio, E. A., Ramos, J. M. P., Bussi, C., Avalos, M. P., Cancela, L. M., & Iribarren, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00770 · Cited by 15
“org April 2018 | Volume 9 | Article 770 Although no solid evidence about the role of MC autophagy on brain inflammation has emerged, recent research showed that neuronal TLR2 activation has been associated with the increased levels of the autophagy/lysosomal pathway marker p62 as well as with the recruitment and activ…”
BackgroundLuca, C. M. G. D., Consonni, A., Cazzaniga, F. A., Bistaffa, E., Bufano, G., Quitarrini, G., Celauro, L., Legname, G., Eleopra, R., Baggi, F., et al. (2021) · Cells · doi:10.3390/cells11010087 · Cited by 16
“Remarkably, toll-like receptor (TLR) signaling is a major pathway mediating inflammation, and TLR2 expression is known to be increased in PD [12,13].”
BackgroundSynucleinopathies Take Their Toll: Are TLRs a Way to Go?
Mazzotta, G. M., Ceccato, N., & Conte, C. (2023) · Cells · doi:10.3390/cells12091231 · Cited by 13
Seong, K.-J., Kim, H.-J., Cai, B., Kook, M.-S., Jung, J., & Kim, W.-J. (2018) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2018.22.2.145 · Cited by 15
“TLR2 can induce pro-inflammatory chemokines and pro-apoptotic proteins affected by microenvironment or damage [22-24].”
Backgroundα-Synuclein 2.0 — Moving towards Cell Type Specific Pathophysiology
Thakur, P. S., Chiu, W., Roeper, J., & Goldberg, J. A. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.06.005 · Cited by 15
Grünenwald, F., Huerta, T. J., Sepúlveda, D., Jerez, C., Urbina, V., Carrera, B., Díaz‐Espinoza, R., Nova, E., Pacheco, R., Martín‐Montañez, E., et al. (2025) · Aging Cell · doi:10.1111/acel.70020 · Cited by 12
Sobrinho, H. M. D. R., Gomes, R. S., da Silva, D. J., Quixabeira, V. B. L., Joosten, L. A. B., Cardoso, C. R. D. B., & Ribeiro‐Dias, F. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24916 · Cited by 13
Habas, A., Natala, S. R., Bowden-Verhoek, J. K., Stocking, E. M., Price, D. L., Wrasidlo, W., Bonhaus, D. W., & Gill, M. B. (2022) · International Journal of Inflammation · doi:10.1155/2022/2337363 · Cited by 17
“Moreover, in the case of PD, the magnitude and distribution of increased TLR2 receptor expression have been found to be correlated with the duration of the disease and the regional deposition of the disease-associated protein alpha-synuclein [33, 48].”
BackgroundMagalhães, J. D., Esteves, A. R., Candeias, E., Silva, D. F., Empadinhas, N., & Cardoso, S. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054339 · Cited by 14
“A study revealed that neuronal TLR2 is specifically upregulated in the anterior cingulate cortex and substantia nigra in PD [26].”
BackgroundDeveloping a biomarker for restless leg syndrome using genome wide DNA methylation data
Roy, A., Earley, C. J., Allen, R. P., & Kaminsky, Z. A. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.12.017 · Cited by 11
Cossais, F., Schaeffer, E., Heinzel, S., Zimmermann, J., Niesler, B., Röth, R., Rappold, G., Scharf, A., Zorenkov, D., Lange, C., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202258 · Cited by 11
Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease
Page, M. J., & Pretorius, E. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1733960 · Cited by 12
Степченко, А. Г., Portseva, T. N., Glukhov, I. A., Котнова, А. П., Lyanova, B. M., Georgieva, S. G., & Pankratova, E. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-98323-y · Cited by 10
Su, W., Gu, X., Hou, Y., Zhang, L., Cao, B., Ou, R., Wu, Y., Chen, X., Song, W., Zhao, B., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.765833 · Cited by 11
Sánchez-González, R., Koupourtidou, C., Lepko, T., Zambusi, A., Novoselc, K. T., Đurović, T., Aschenbroich, S., Schwarz, V., Breunig, C., Straka, H., et al. (2022) · Cells · doi:10.3390/cells11030520 · Cited by 13
“As we did not perform cell-specific interference and because both receptors are expressed in several cell types (microglia/monocytes [111,112]; astrocytes [113,114]; oligodendroglia [114]; neurons [113,115]), we cannot exclude the possibility that other cell types contribute to the induction of the wound closure via t…”
BackgroundIdentification of TLR2 as a Key Target in Neuroinflammation in Vascular Dementia
Wang, Y., Lv, S., Zhou, X., Niu, X., Chen, L., Yang, Z., & Peng, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.860122 · Cited by 12
“At last, the expression levels of inflammatory cytokines increased (Brea et al., 2011; Dzamko et al., 2017; Sun et al., 2017).”
BackgroundKumari, M., Hanpude, P., & Maiti, T. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00480 · Cited by 10
Khan, Z., & Jung, Y. J. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00052 · Cited by 9
Dietary flavonoids: Promising compounds for targeting α-synucleinopathy in Parkinson’s disease
Harati, M., Tayarani‐Najaran, Z., & Javadi, B. (2023) · PharmaNutrition · doi:10.1016/j.phanu.2023.100334 · Cited by 9
Therapeutic Effects of the major alkaloid constituents of Evodia rutaecarpa in Alzheimer's disease
Cao, Q., Dong, P., & Han, H. (2024) · Psychogeriatrics · doi:10.1111/psyg.13051 · Cited by 10
“39 Consequently, modulating TLR2-mediated microglia or macrophage activation has been suggested as a key strategy for treating neurodegenerative diseases.”
BackgroundLabrador‐Garrido, A., Zhong, S., Hughes, L. P., Keshiya, S., Kim, W. S., Halliday, G. M., & Dzamko, N. L. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1229213 · Cited by 9
Self-citationDPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease
Jeong, S. H., Kim, Y. J., Shin, J. Y., Oh, K. W., Lee, J. W., & Lee, P. H. (2025) · Gut · doi:10.1136/gutjnl-2025-334988 · Cited by 10
Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?
Satyanarayanan, S. K., Yip, T. F., Han, Z., Zhu, H., Qin, D., & Lee, S. M.-Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1458281 · Cited by 8
“TLR2 is found in microglia, neurons, and within Lewy bodies, indicating its widespread involvement in the pathogenesis of PD (166).”
Zuo, X., Ju, C., Zhang, Z., Wei, X., Ma, Y., Song, Z., Zhang, J., Luo, L., Zhu, Z., Wang, Z., et al. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.03.014 · Cited by 8
Gupta, A. K., Rani, K., Swarnkar, S., Kumar, G. K., Khan, M. I., Pokhriyal, R., Kumar, D. R., Goyal, V., Tripathi, M., Gupta, R., et al. (2018) · Journal of Central Nervous System Disease · doi:10.1177/1179573518803585 · Cited by 8
Gupta, A. K., Pokhriyal, R., Das, U., Khan, M. I., Kumar, D. R., Gupta, R., Chadda, R. K., Ramachandran, R., Goyal, V., Tripathi, M., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s205550 · Cited by 8
Khodadadi, M., & Javadi, B. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575306884240604065754 · Cited by 7
Design of Ig-like binders targeting α-synuclein fibril for mitigating its pathological activities
Zeng, S., Xiong, X., Long, H., Xu, Q., Yu, Y., Sun, B., Liu, C., Wang, Z., Xu, W., Zhang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62755-1 · Cited by 7
Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein
Ganguly, U., Singh, S., Chakrabarti, S., Saini, A. K., & Saini, R. V. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2021.11.010 · Cited by 7
Liang, Y. Q., Zhou, L., Liu, H., Huang, X., Lǐ, Y., Li, X., & Huang, S. (2025) · Experimental Neurobiology · doi:10.5607/en25022 · Cited by 6
Parkinson’s disease: genetics and neuroinflammatory insights
Chandel, I., Kumari, S., Bagri, K., Bhatia, A., & Deshmukh, R. R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01832-9 · Cited by 8
“Level of neuronal TLR2 is higher in the PD patients as compared to glial TLR2 and is associated with the progression of PD (Drouin-Ouellet et al. 2015; Dzamko et al. 2017).”
Sossi, V. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.034 · Cited by 7
Kaya, Z. B., Karakoç, E., McLean, P. J., Saka, E., & Atilla, P. (2023) · FASEB BioAdvances · doi:10.1096/fba.2022-00145 · Cited by 7
Molecular Basis of Neurological Disorders
Singh, G., Rao, D., & Kumar, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821974-4.00014-5 · Cited by 6
Nutraceuticals a Food for Thought in the Treatment of Parkinson’s Disease
Bansal, K., Singh, S., Singh, V., & Bajpai, M. (2023) · Current Nutrition & Food Science · doi:10.2174/1573401319666230515104325 · Cited by 5
Metadata
- Authors
- Dzamko, N., Gysbers, A., Perera, G., Bahar, A., Shankar, A., Gao, J., Fu, Y., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- Corresponding author
- Dzamko, Nicolas
- Halliday, Glenda M.
- Venue
- Acta Neuropathologica
- Published
- 2016-11-25
- Volume
- 133
- Issue
- 2
- Pages
- 303-319
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC5250664
- OpenAlex
- W2554874133
- Semantic Scholar
- 6d5ed92f5026eb13731b365c8793acdf5588d2a7
- Cited by
- 273
- References
- 49
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 34 · 2023: 35 · 2022: 42 · 2021: 40 · 2020: 26 · 2019: 23 · 2018: 24 · 2017: 12
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council
- Parkinson's NSW
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, TLR2, alpha-synuclein, neuroinflammation, Lewy bodies, microglia, autophagy, p62, reactive oxygen species, inflammatory cytokines, chemokines, disease staging, rapamycin, TLR2 signaling
- MeSH terms
- Aged, Aged, 80 and over, Brain, Female, Humans, Inflammation, Male, Middle Aged, Parkinson Disease, Toll-Like Receptor 2, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.